Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a ...
The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat ...
The European Commission has cleared use of CDK4/6 inhibitor Kisqali (ribociclib) to reduce the risk of recurrence in patients ...
Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...
Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Winrevair was approved to treat PAH WHO Group 1 in the United States in March based on data from the STELLAR study.
Novartis’ Kisqali (ribociclib) has been approved by the European Commission (EC) to reduce the risk of disease recurrence in ...
Novartis (NVS) said that the European Commission has approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the ...
Novartis (NVS) announced that the European Commission, EC, has approved Kisqali in combination with an aromatase inhibitor, AI, for the ...
Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a broad population. The EC has approved Kisqali in combination with an ...
Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...
Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...